Drug discovery innovator Magnitude Biosciences lands £700k funding

Magnitude Biosciences secures over £700,000 to accelerate in vivo high-throughput drug discovery platform

Magnitude Biosciences, a specialist contract research organisation (CRO) in County Durham offering in vivo discovery of treatments for age-related conditions and other diseases using C. elegans, has secured over £700,000 in combined funding to scale up its high-throughput screening (HTS) platform.

County Durham biosciences firm boosted by £700,000 backing with promise of jobs

NETPark based healthcare firm says it will “accelerate its mission to revolutionise drug discovery” after securing more than £700,000 support.

Drug discovery innovator Magnitude Biosciences lands £700k funding

A new funding round led by Maven and featuring existing backer Northstar Ventures aims to scale delivery of the firm's technology